---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-037689"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2024-12-17T23:59:59+00:00"
generated_at: "2026-05-29T02:28:35.592263+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eton Pharma announces PKU GOLIKE trial shows statistically significant metabolic control improvement

## Summary
- PKU GOLIKE showed statistically significant reduction in blood Phe (P=0.0002) and increase in Tyr (P=0.0113) vs standard substitutes during overnight fasting.
- Average 17.8% reduction in Phe (P=0.0484) and 33.8% increase in Tyr (P=0.0008) from baseline with PKU GOLIKE; standard substitutes led to 27.6% Phe increase.
- Study was randomized crossover in pediatric classical PKU patients at Birmingham Children's Hospital; results to be presented at ACMG 2025.
- Eton expects data to promote adoption of PKU GOLIKE; product is marketed via existing metabolic sales force.

## SEC filing metadata
- accession: 0001437749-24-037689
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2024-12-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774924037689/0001437749-24-037689-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774924037689/eton20241216_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-037689
- JSON: https://secwatch.observer/filing/0001437749-24-037689.json
- Plain text: https://secwatch.observer/filing/0001437749-24-037689.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.